Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
7
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
7
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
medicare
merck
pfizer
abbvie
alzheimer's disease
amgen
cancer
deals
diagnostics
drug prices
eli lilly
president trump
What
drug
7
×
bio
roundup
new
acquisitions
approval
biggest
ceo
companies
patients
pharmaceutical
plan
price
prices
today
advantages
albert
alzheimer’s
amgen
away
bar
biogen’s
biopharmaceutical
bourla
bringing
brings
build
buy
candidates
ceos
class
company
company’s
convo
crispr
daniel
dc
debut
developed
different
Language
unset
unknown
Current search:
drug
×
biotech
×
novartis
×
" detroit blog main "
×
" san diego top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines